ONCOC4, INC.
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://oncoc4.com
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT06635785
- Locations
- 🇺🇸
The Ohio State University James Cancer Center, Columbus, Ohio, United States
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06352359
- Locations
- 🇺🇸
University of California at Davis Cancer Center, Sacramento, California, United States
🇺🇸Norton Cancer Center, Louisville, Kentucky, United States
🇺🇸Tranquil Clinical Research, Houston, Texas, United States
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- OncoC4, Inc.
- Registration Number
- NCT06219499
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05858736
- Locations
- 🇦🇺
Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
🇦🇺Mater Misericordiae Ltd., Brisbane, Queensland, Australia
🇦🇺Tasman Oncology Research, Southport, Queensland, Australia
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT05682443
- Locations
- 🇺🇸
University of California at Davis Cancer Center - 1624, Davis, California, United States
🇺🇸Rocky Mountain Cancer Center USOR - 1633, Aurora, Colorado, United States
🇺🇸Moffitt Cancer Cancer- 1605, Tampa, Florida, United States
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05671510
- Locations
- 🇦🇺
Bankstown Hospital - 3305, Bankstown, New South Wales, Australia
🇦🇺Newcastle Private Hospital - 3302, New Lambton Heights, New South Wales, Australia
🇦🇺Mater - 3301, Newstead, Queensland, Australia
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05446298
- Locations
- 🇺🇸
Cancer Treatment Centers of America, Phoenix. 403, Goodyear, Arizona, United States
🇺🇸Honor Health, USOR, 406, Phoenix, Arizona, United States
🇺🇸Nuvance Health System, 401, Danbury, Connecticut, United States
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 733
- Registration Number
- NCT04140526
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The Oncology Institute of Hope and Innovation, Downey, California, United States
🇺🇸University of California at Davis, Davis, California, United States